All approved antibody therapies for Covid-19 are ineffective against the Omicron sub-lineage BQ.1.1.
That’s the worrying news following a recent study by researchers at the German Primate Center (DPZ) – Leibniz Institute for Primate Research and Friedrich-Alexander University Erlangen-Nürnberg.
Omicron sub-variant BQ.1.1 is currently on the rise worldwide.
As a result of an infection with the SARS coronavirus-2 (SARS-CoV-2) or a Covid-19 vaccination, an immune response is triggered that entails the formation of neutralizing antibodies that help protect against (re)infection with SARS-CoV-2 or a severe course of the disease.
Neutralizing antibodies protect by binding to the viral spike protein, which prevents the virus from entering cells. However, due to mutations in the spike protein, some SARS-CoV-2 variants, particularly the Omicron variant, evade neutralizing antibodies and cause symptomatic infections even in vaccinated or convalescent persons.
This is referred to as immune evasion and threatens high-risk groups such as the elderly and people with weakened immune systems, for example, due to illness or medication. They often fail to develop an immune response sufficient for protection from severe disease, even after full vaccination.
To protect high-risk patients, biotechnologically produced antibodies are administered as a preventive measure or as an early therapy upon confirmed SARS-CoV-2 infection. Mutations in the spike protein of different SARS-CoV-2 variants confer resistance to individual antibody therapies. Therefore, it is important to regularly monitor whether therapeutic antibodies continue to be effective against currently circulating viral variants.
Omicron subvariant BQ.1.1 resistant to all antibody therapies
“For our studies, we mixed non-propagating viral particles carrying the spike protein of selected viral variants with different dilutions of the antibodies to be tested and subsequently measured the amount of antibody needed to inhibit infection of cell cultures. In total, we tested twelve individual antibodies, six of which are approved for clinical use in Europe, and four antibody cocktails,” said Prerna Arora, lead author of the study.
The researchers found that the Omicron subvariant BQ.1.1 could not be neutralized by either individual antibodies or antibody cocktails. In contrast, the currently predominant Omicron subvariant BA.5 was still neutralized by one approved antibody and two approved antibody cocktails.
“With high-risk patients in mind, we are very concerned about the Omicron subvariant BQ.1.1 being resistant to all approved antibody therapies. Particularly in regions where BQ.1.1 is widespread, physicians should not rely on antibody therapies alone when treating infected high-risk patients, but should also consider administering other drugs such as paxlovid or molnupiravir,” said study leader Markus Hoffmann.
The finding that the Omicron subvariant BQ.1.1 is already resistant to a new antibody therapy that is about to be approved in the U.S. highlights the importance of developing new antibody therapies against Covid-19.
“The ever-increasing development of antibody resistance of SARS-CoV-2 variants calls for the development of new antibody therapies that are specifically targeted to currently circulating and future viral variants. Ideally, they should target regions in the spike protein that have little potential for escape mutations,” concluded Stefan Pöhlmann, head of the Infection Biology Unit at the German Primate Center – Leibniz Institute for Primate Research.
However, last week Moderna announced that its BA.4/BA.5 targeting bivalent booster, MRNA-1273.222, showed neutralizing titers against BQ.1.1, an emerging threat globally, in an exploratory analysis.
“We are pleased to see that both of our bivalent booster vaccine candidates offer superior protection against Omicron BA.4/BA.5 variants compared to our original booster, which is encouraging given Covid-19 remains a leading cause of hospitalization and death globally. In addition, the superior response against Omicron persisted for at least three months after the mRNA-1273.214 booster,” said Stéphane Bancel, Moderna’s chief executive officer.
“Our bivalent boosters also show, in research assays, neutralizing activity against BQ.1.1, an increasingly dominant emerging variant, confirming that updated vaccines have the potential to offer protection as the virus continues to evolve rapidly to escape our immunity.”
Online partnering event with academia